LNA043
Sponsors
Novartis Pharma AG, Novartis Pharmaceuticals
Conditions
KneeKnee Cartilage LesionKnee OsteoarthritisOsteoarthritisPrimary Osteoarthritis Patients Scheduled for Total Knee Replacement Surgery
Phase 1
First-in-human Single Ascending Dose Study of LNA043 in Patients Scheduled for Total Knee Replacement
CompletedNCT02491281
Start: 2015-11-16End: 2018-03-06Updated: 2020-12-11
Study of Safety, Tolerability and Pharmacokinetics of LNA043 in Japanese Osteoarthritis Participants
CompletedNCT04564053
Start: 2020-09-23End: 2020-12-10Updated: 2022-08-10
Phase 2
Study of Safety, Tolerability, Preliminary Efficacy of Intra-articular LNA043 Injections in Patients With Articular Cartilage Lesions and Knee Osteoarthritis.
CompletedNCT03275064
Start: 2017-09-12End: 2022-09-06Updated: 2026-04-21
Study on Safety, Tolerability and Prelimenary Efficacy of LNA043 in Patients Undergoing Autologous Chondrocyte Implantation
TerminatedNCT03334812
Start: 2017-10-18End: 2019-04-05Updated: 2021-10-07
A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA)
TerminatedNCT04814368
Start: 2021-08-27End: 2024-06-24Updated: 2025-10-24
Study of Efficacy, Safety, and Tolerability of LNA043 in Patients With Knee Osteoarthritis
TerminatedNCT04864392
Start: 2021-05-31End: 2025-05-29Updated: 2026-04-02
A 5- year randomized, double-blind, placebo-controlled, multi-center study assessing the efficacy, safety, and tolerability of intra-articular regimens of LNA043 versus placebo in patients with symptomatic knee osteoarthritis (ONWARDS)
CompletedCTIS2023-509937-37-00
Start: 2021-07-21End: 2025-05-27Target: 250Updated: 2024-11-27